Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06859762 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
19
Study locations

NCT06859762: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

NCT06859762 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 220 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher). The trial reports 19 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06859762, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
19
Study locations

Study Summary

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

Primary Outcome

The purpose of DLT is to find maximum tolerated dose (MTD).

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG YL217

Study Locations (19)

Ohio

  • University of Cincinnati Medical Center - Cincinnati
  • Cleveland Clinic Taussig Cancer Institute - Cleveland

Texas

  • The University of Texas MD Anderson Cancer Center - Houston
  • UT Health San Antonio - Mays Cancer Center - San Antonio

Arizona

  • Mayo Clinic Arizona - Phoenix

California

  • UCLA Hematology/Oncology - Santa Monica - Santa Monica

Connecticut

  • Yale Cancer Center - New Haven

Kansas

  • The University of Kansas Cancer Center (KUCC) - Kansas City

Maryland

  • University of Maryland Medical Center-Greenebaum Cancer Ctr - Medical Oncology - Baltimore

Michigan

  • Karmanos Cancer Institute - Detroit

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2025-07-02
Est. Completion 2027-07
Phase Phase 1
MediLink Therapeutics (Suzhou) Co.

7 total trials

What NCT06859762 shows while recruiting

NCT06859762 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (15% higher).

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which YL217 is the first listed.

NCT06859762 lists 19 locations in 17 states (Ohio, Texas, Arizona).

Frequently Asked Questions

What is clinical trial NCT06859762 about?

NCT06859762 is a clinical study titled "A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors". A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors

What is the current status of trial NCT06859762?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-07-02. Estimated completion is 2027-07.

What conditions does trial NCT06859762 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06859762?

The interventions under investigation include: YL217 (DRUG).

Who is sponsoring clinical trial NCT06859762?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06859762 being conducted?

This trial has 19 study locations across Arizona, California, Connecticut, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06859762's enrollment target sits among peer trials

220 55th of 189 higher than 132 of 189 other Advanced Solid Tumor trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06859762

Source: ClinicalTrials.gov NCT06859762, the US trial registry maintained by the National Library of Medicine. NCT06859762 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.